Guardian Pharmacy Services Inc

GRDN remains in a Stage 2 advance with intact long-term uptrend. The recent pullback into the rising 9/21 EMAs has repaired the corrective reset but lacks clear follow-through to confirm a new leg higher. Medium-term bias stays bullish, yet short-term overbought and consolidation dynamics warrant patience. Execution should focus on pullback interactions into the EMAs, awaiting reclaim and acceptance before committing.

• ↑Revenue +20% YoY to $329M, cash balance grew by $60M
• ↑Adjusted EBITDA +16% to $23.4M, margin steady at 7.2%
• ↓IRA triggered ~60% price decline on impacted branded drugs